Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.

BACKGROUND: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study describes the course of depressive symptoms, perceived cognitive symptoms, and functional impairment over 2 years in outpatients with major depressive disorder (MDD) and...

ver descrição completa

Detalhes bibliográficos
Autores: Hammer-Helmich L, Haro JM, Jönsson B, Tanguy Melac A, Di Nicola S, Chollet J, Milea D, Rive B, Saragoussi D
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Recursos:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p13536
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13536
Access Level:acceso abierto
Palavra-chave:cognition
depression
functional impairment
functioning
major depressive disorder
id ES_e6c4503dd7b9c2df23ed3546f8bca633
oai_identifier_str oai:fsjd.fundanetsuite.com:p13536
network_acronym_str ES
network_name_str España
repository_id_str
spelling Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.Hammer-Helmich LHaro JMJönsson BTanguy Melac ADi Nicola SChollet JMilea DRive BSaragoussi Dcognitiondepressionfunctional impairmentfunctioningmajor depressive disorderBACKGROUND: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study describes the course of depressive symptoms, perceived cognitive symptoms, and functional impairment over 2 years in outpatients with major depressive disorder (MDD) and investigates the patient-related factors associated with functional impairment. METHODS: This was a 2-year observational study in 1,159 outpatients with MDD aged 18-65 years who were either initiating antidepressant monotherapy or undergoing their first switch of antidepressant. Functional impairment was assessed by the Sheehan Disability Scale and the Work Productivity and Activity Impairment questionnaire. Patients assessed depression severity using the nine-item Patient Health Questionnaire and severity of perceived cognitive symptoms using the five-item Perceived Deficit Questionnaire. To investigate which patient-related factors were associated with functional impairment, univariate analyses of variance were performed to identify relevant factors that were then included in multivariate analyses of covariance at baseline, month 2, months 6 and 12 combined, and months 18 and 24 combined. RESULTS: The greatest improvement in depressive symptoms, perceived cognitive symptoms, and functional impairment was seen immediately (within 2 months) following initiation or switch of antidepressant therapy, followed by more gradual improvement and long-term stabilization. Improvement in perceived cognitive symptoms was less marked than improvement in depressive symptoms during the acute treatment phase. Functional impairment in patients with MDD was not only associated with severity of depressive symptoms but also independently associated with severity of perceived cognitive symptoms when adjusted for depression severity throughout the 2 years of follow-up. CONCLUSION: These findings highlight the burden of functional impairment in MDD and the importance of recognizing and managing cognitive symptoms in daily practice.DOVE MEDICAL PRESS LTD2018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13536Neuropsychiatric Disease and TreatmentISSN: 11766328ISSNe: 11782021reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p135362026-05-27T12:37:41Z
dc.title.none.fl_str_mv Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
title Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
spellingShingle Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
Hammer-Helmich L
cognition
depression
functional impairment
functioning
major depressive disorder
title_short Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
title_full Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
title_fullStr Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
title_full_unstemmed Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
title_sort Functional impairment in patients with major depressive disorder: the 2-year PERFORM study.
dc.creator.none.fl_str_mv Hammer-Helmich L
Haro JM
Jönsson B
Tanguy Melac A
Di Nicola S
Chollet J
Milea D
Rive B
Saragoussi D
author Hammer-Helmich L
author_facet Hammer-Helmich L
Haro JM
Jönsson B
Tanguy Melac A
Di Nicola S
Chollet J
Milea D
Rive B
Saragoussi D
author_role author
author2 Haro JM
Jönsson B
Tanguy Melac A
Di Nicola S
Chollet J
Milea D
Rive B
Saragoussi D
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv cognition
depression
functional impairment
functioning
major depressive disorder
topic cognition
depression
functional impairment
functioning
major depressive disorder
description BACKGROUND: The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (PERFORM) study describes the course of depressive symptoms, perceived cognitive symptoms, and functional impairment over 2 years in outpatients with major depressive disorder (MDD) and investigates the patient-related factors associated with functional impairment. METHODS: This was a 2-year observational study in 1,159 outpatients with MDD aged 18-65 years who were either initiating antidepressant monotherapy or undergoing their first switch of antidepressant. Functional impairment was assessed by the Sheehan Disability Scale and the Work Productivity and Activity Impairment questionnaire. Patients assessed depression severity using the nine-item Patient Health Questionnaire and severity of perceived cognitive symptoms using the five-item Perceived Deficit Questionnaire. To investigate which patient-related factors were associated with functional impairment, univariate analyses of variance were performed to identify relevant factors that were then included in multivariate analyses of covariance at baseline, month 2, months 6 and 12 combined, and months 18 and 24 combined. RESULTS: The greatest improvement in depressive symptoms, perceived cognitive symptoms, and functional impairment was seen immediately (within 2 months) following initiation or switch of antidepressant therapy, followed by more gradual improvement and long-term stabilization. Improvement in perceived cognitive symptoms was less marked than improvement in depressive symptoms during the acute treatment phase. Functional impairment in patients with MDD was not only associated with severity of depressive symptoms but also independently associated with severity of perceived cognitive symptoms when adjusted for depression severity throughout the 2 years of follow-up. CONCLUSION: These findings highlight the burden of functional impairment in MDD and the importance of recognizing and managing cognitive symptoms in daily practice.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13536
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13536
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
dc.source.none.fl_str_mv Neuropsychiatric Disease and Treatment
ISSN: 11766328
ISSNe: 11782021
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422795506581504
score 15.812455

Registos relacionados